Improving the Efficacy of Cancer mRNA Vaccines DOI
Ameya R. Kirtane, Giovanni Traverso

The Cancer Journal, Journal Year: 2025, Volume and Issue: 31(2)

Published: March 1, 2025

mRNA vaccines consist of antigen-encoding mRNA, which produces the antigenic protein upon translation. Coupling antigen production with innate immune activation can generate a potent, antigen-specific T-cell response. Clinical reports have demonstrated ability to elicit an anticancer response against various tumor types. Here, we discuss strategies enhance potency vaccines. We provide overview existing knowledge regarding and trafficking mechanisms share optimization boost mRNA-mediated production. In addition, address methods target dendritic cells lymph nodes, key initiators Finally, review for enhancing using adjuvants compatible offer unique advantages that be utilized oncology applications. However, significant work is needed understand their underlying develop technologies improve effectiveness.

Language: Английский

Exploring the Potential of Nanocarriers for Cancer Immunotherapy: Insights into Mechanism, Nanocarriers, and Regulatory Perspectives DOI

Tanmoy Kanp,

Anish Dhuri,

M Bharath

et al.

ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 10, 2025

Immunotherapy is a cutting-edge approach that leverages sophisticated technology to target tumor-specific antibodies and modulate the immune system eradicate cancer enhance patients' quality of life. Bioinformatics genetic science advancements have made it possible diagnose treat patients using immunotherapy technology. However, current immunotherapies against limited clinical benefits due cancer-associated antigens, which often fail interact with cells exhibit insufficient therapeutic targeting unintended side effects. To surmount this challenge, nanoparticle systems emerged as potential strategy for transporting immunotherapeutic agents activating combat tumors. Consequently, process potentially generates an antigen-specific T response effectively suppresses growth. Furthermore, nanoplatforms high specificity, efficacy, diagnostic potential, imaging capabilities, making them promising tools treatment. informative paper delves into various available immunotherapies, including CAR therapy checkpoint blockade, cytokines, vaccines, monoclonal antibodies. concept theragnostic nanotechnology, integrates diagnostics more personalized treatment therapy. Additionally, covers different nanocarrier systems, marketed products, trials, regulatory considerations, future prospects immunotherapy.

Language: Английский

Citations

1
Recent Progress in Cancer Vaccines and Nanovaccines DOI
Kishwor Poudel,

Tulasi Vithiananthan,

Jong Oh Kim

et al.

Biomaterials, Journal Year: 2024, Volume and Issue: 314, P. 122856 - 122856

Published: Sept. 28, 2024

Language: Английский

Citations

4
Improving the Efficacy of Cancer mRNA Vaccines DOI
Ameya R. Kirtane, Giovanni Traverso

The Cancer Journal, Journal Year: 2025, Volume and Issue: 31(2)

Published: March 1, 2025

mRNA vaccines consist of antigen-encoding mRNA, which produces the antigenic protein upon translation. Coupling antigen production with innate immune activation can generate a potent, antigen-specific T-cell response. Clinical reports have demonstrated ability to elicit an anticancer response against various tumor types. Here, we discuss strategies enhance potency vaccines. We provide overview existing knowledge regarding and trafficking mechanisms share optimization boost mRNA-mediated production. In addition, address methods target dendritic cells lymph nodes, key initiators Finally, review for enhancing using adjuvants compatible offer unique advantages that be utilized oncology applications. However, significant work is needed understand their underlying develop technologies improve effectiveness.

Language: Английский

Citations

0